Targeted treatment with anti-TREM2 monoclonal antibody can produce potent anti-tumor immune effects, inhibit tumor growth, and also enhance the anti-PD-1 immunotherapeutic response and improve the therapeutic effect of ICIs, making it an effective target for cancer immunotherapy. The gene discussed is TREM2; the disease is cancer.